Repositioning Candidate Details
| Candidate ID: | R0174 |
| Source ID: | DB00509 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Dextrothyroxine |
| Synonyms: | D-thyroxine; Dextrothyroxine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine |
| Molecular Formula: | C15H11I4NO4 |
| SMILES: | N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O |
| Structure: |
|
| DrugBank Description: | The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. |
| CAS Number: | 51-49-0 |
| Molecular Weight: | 776.87 |
| DrugBank Indication: | Used to lower high cholesterol levels in the blood. |
| DrugBank Pharmacology: | Dextrothyroxine, the dextrorotary isomer of the synthetic thyroxine, is a antihyperlipidemic. |
| DrugBank MoA: | Dextrothyroxine is a antihyperlipidemic. The mechanism of action is not completely understood, but dextrothyroxine apparently acts in the liver to stimulate formation of low-density lipoprotein (LDL) and, to a much greater extent, to increase catabolism of LDL. This leads to increased excretion of cholesterol and bile acids via the biliary route into the feces, with a resulting reduction in serum cholesterol and LDL. Dextrothyroxine has no significant effect on high-density lipoproteins (HDL). Inherently, it will also bind to thyroid receptors and as it is a prohormone, it will bind as a substrate to iodide peroxidase. |
| Targets: | Thyroid hormone receptor alpha agonist; Thyroid hormone receptor beta agonist; Thyroid peroxidase |
| Inclusion Criteria: | Target associated |
